Insider Buying: KORU Medical Systems (NASDAQ:KRMD) COO Acquires $19,400.00 in Stock

KORU Medical Systems, Inc. (NASDAQ:KRMD) COO Christopher Pazdan acquired 5,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was purchased at an average cost of $3.88 per share, for a total transaction of $19,400.00. Following the completion of the acquisition, the chief operating officer owned 305,131 shares in the company, valued at approximately $1,183,908.28. This represents a 1.67% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

KORU Medical Systems Price Performance

Shares of NASDAQ KRMD opened at $4.00 on Thursday. The stock’s fifty day moving average price is $4.19 and its two-hundred day moving average price is $4.84. KORU Medical Systems, Inc. has a one year low of $2.63 and a one year high of $6.61. The firm has a market cap of $183.72 million, a price-to-earnings ratio of -80.00 and a beta of 0.43.

KORU Medical Systems (NASDAQ:KRMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The firm had revenue of $11.76 million for the quarter, compared to analyst estimates of $11.28 million. On average, equities analysts anticipate that KORU Medical Systems, Inc. will post -0.04 earnings per share for the current fiscal year.

Institutional Trading of KORU Medical Systems

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its position in shares of KORU Medical Systems by 52.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after buying an additional 3,478 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of KORU Medical Systems during the 2nd quarter worth $59,000. Acadian Asset Management LLC bought a new stake in shares of KORU Medical Systems during the 1st quarter worth $63,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of KORU Medical Systems during the 1st quarter worth $79,000. Finally, Invesco Ltd. bought a new stake in shares of KORU Medical Systems during the 2nd quarter worth $80,000. 58.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a report on Tuesday, April 21st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of KORU Medical Systems in a report on Friday, March 13th. Wall Street Zen lowered KORU Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, B. Riley Financial upped their price objective on KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.